Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Calvert

Showing results (201-210 of 220) with videos related to

Pageof 22
Sort By:
Journal of Animal Science|March 17, 2009
Impact of water troughs on cattle use of riparian zones in the Georgia Piedmont in the United StatesD H Franklin, M L Cabrera, H L Byers, et al.
British Journal of Cancer|March 10, 2005
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigationsA Azzabi, A N Hughes, P M Calvert, et al.
British Journal of Cancer|February 3, 2011
A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumoursR Plummer, R H Wilson, H Calvert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumorsI Rafi, A V Boddy, J A Calvete, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2002
Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedulesA B Simpson, P M Calvert, J A Sludden, et al.
Journal of Medicinal Chemistry|November 7, 2000
Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanineR J Griffin, C E Arris, C Bleasdale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor typesJ Baselga, D Rischin, M Ranson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2011
A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancerG Rustin, N Reed, G C Jayson, et al.
British Journal of Cancer|August 31, 2013
Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanomaR Plummer, P Lorigan, E Brown, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1982
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum IIA H Calvert, S J Harland, D R Newell, et al.
Pageof 22

Showing results (201-210 of 220) with videos related to

Sort By:
Pageof 22
Journal of Animal Science|March 17, 2009
Impact of water troughs on cattle use of riparian zones in the Georgia Piedmont in the United StatesD H Franklin, M L Cabrera, H L Byers, et al.
British Journal of Cancer|March 10, 2005
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigationsA Azzabi, A N Hughes, P M Calvert, et al.
British Journal of Cancer|February 3, 2011
A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumoursR Plummer, R H Wilson, H Calvert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumorsI Rafi, A V Boddy, J A Calvete, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2002
Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedulesA B Simpson, P M Calvert, J A Sludden, et al.
Journal of Medicinal Chemistry|November 7, 2000
Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanineR J Griffin, C E Arris, C Bleasdale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor typesJ Baselga, D Rischin, M Ranson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2011
A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancerG Rustin, N Reed, G C Jayson, et al.
British Journal of Cancer|August 31, 2013
Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanomaR Plummer, P Lorigan, E Brown, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1982
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum IIA H Calvert, S J Harland, D R Newell, et al.
Pageof 22